The MEta-analysis of Risk Improvement under Acarbose (MeRIA), which analysed the results of seven long-term trials carried out in patients with type 2 diabetes, confirmed that treatment with acarbose has broader benefits for the management of vascular disease and damage [21]
ALWAYS CONSULT YOUR PHYSICIAN BEFORE BEGINNING ANY TREATMENT PROGRAM
25 The bulk of the remaining 10% of the patients are diagnosed with type 1 diabetes (T1D), although other types exist that are rare
GLP-1 users who kept THEIR HAIR
Core outcome sets should encompass HbA1c, fasting plasma glucose, HOMA-IR, CRP, IL-6, TNF-, MDA, lipid profiles (total cholesterol, LDL-cholesterol, HDL-cholesterol, triglycerides), anthropometric indices (body mass index, waist circumference), adverse events, and any modifications to background antidiabetic pharmacotherapy
L.LunaE.RhoadesN.PodarM.et al